U.S. FDA approves CAPVAXIVE (V116), specifically designed for pneumococcal disease in adults EP News Bureau Jun 18, 2024 Across four Phase 3 studies, CAPVAXIVE demonstrated robust immune responses in both vaccine-naïve and vaccine-experienced adult…
Merck gets US FDA nod of adult pneumococcal 15-valent conjugate vaccine EP News Bureau Jul 17, 2021 VAXNEUVANCE demonstrated non-inferior immune responses for the serotypes shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C,…
Serum Institute of India launches indigenously developed pneumococcal vaccine,… EP News Bureau Dec 28, 2020 This WHO pre-qualified PCV is specially tailored to the prevailing serotype prevalence of S. pneumoniae in India and other regions…
